Resverlogix Corp., among others including Dr. Norman Wong, Chief Scientific Officer of Resverlogix, has
been named as a defendant in a statement of claim filed by the University of Calgary in January 2006, as
amended in March 2006. In its claim, the University asserts a 35% interest in 4,089,481 common shares
issued by Resverlogix to Dr. Norman Wong, based on the alleged fact that Dr. Wong was issued the
4,089,481 common shares in consideration for a technology developed by Dr. Wong while employed at
the University. The University claims that Resverlogix is a constructive trustee of 35% of such 4,089,481
common shares issued to Dr. Wong or alternatively, a trustee for 35% of the technology sold by Dr. Wong
to Resverlogix, and further claims that Resverlogix has a duty to register these common shares in the
name of the University but has failed to do so. Resverlogix is disputing all of the University's claims,
believes that the University's claims are entirely without merit and that the Company has no material risk
relating to this lawsuit. The Company is confident of its position on the basis that: i) any legitimate claim
of the University is against Dr. Wong not Resverlogix; ii) Dr. Wong has voluntarily set aside and put into
trust 35% of his 4,089,481 common shares pending settlement of the lawsuit; iii) the technology inPage 32 of 42"
If you want to read the rest do a little reseach yourself.